上皮性卵巢癌组织中MEG3基因异常甲基化状态及其临床意义

Methylation state of MEG3 gene in epithelial ovarian cancer and its clinical significanc research

目的：研究在上皮性卵巢癌组织中母系表达基因（MEG3）基因启动子异常甲基化状态与其临床病理特征的关系。方法：运用甲基化特异性聚合酶链反应（MSP）法。检测47例卵巢癌组织（蜡块标本）及15例正常卵巢组织（蜡块标本）中MEG3基因启动子甲基化状态。分析其甲基化状态与临床病理特征的关系。结果：MEG3基因甲基化发生率在卵巢癌组织（42．6％）中高于正常卵巢组织（13．3％），差异有统计学意义（P=0．035）；年龄〉60岁患者MEG3基因甲基化发生率略高于年龄≤60岁。差异无统计学意义（P〉0．05）；临床Ⅲ～Ⅳ期患者MEG3基因甲基化的发生率低于临床Ⅰ～Ⅱ期，差异无统计学意义（P〉0．05）；MEG3基因甲基化阳性率在卵巢癌不同病理分级和组织学类型间未见明显差异（P〉0．05）。结论：MEG3基因异常甲基化可能与上皮性卵巢癌发生相关，与其临床病理无关。

Objective To study the relationship between the methylation status of CPG islands in MEG3 gene promoter region of epithelial ovarian cancer and its clinical and pathological features. Methods The promoter methylation status was evaluated by MSP （methylation-specific polymerase chain reaction） in 47 cases of ovarian cancer tissue and 15 cases of normal control. Results The methylation ratio （42.6%） of the MEG3 genes in the ovarian cancer was statistically significantly higher （P = 0.035 ） than that （13.3%） in the normal control. The methyation rate of the group with an age 〉 60 years old was slightly higher than that of the group with an age ≤60 years old, without statistically significant （P 〉 0.05）, so was observed in ovarian cancers of stage Ⅰ and Ⅱ than that in stage Ⅲ and Ⅳ. There were also no significant differences in MEG3 gene methylation positive rate neither in different pathological grading nor in various ovarian cancer tissues （P 〉 0.05）. Conclusion Abnormal methylation in MEG3 gene may be associated with epithelial ovarian cancer, but no relation to its clinical pathology.